Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178294 · ClinicalTrials.gov registry record · Phase 2
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
A Phase 2 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01178294 is a Phase 2 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 29 participants.
The verdict
NCT01178294, a Phase 2 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
Interventions
- BIOLOGICAL OBI-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-11-10 |
| Est. Completion | 2013-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178294
The ClinicalTrials.gov registry entry for NCT01178294 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OBI-1 is the first listed.
NCT01178294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01178294 about?
NCT01178294 is a clinical study titled "Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A". This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
What is the current status of trial NCT01178294?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-11-10. Estimated completion is 2013-10-09.
What interventions are being tested in trial NCT01178294?
The interventions under investigation include: OBI-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01178294?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.